Trial Profile
Tau pathology using [F-18]AV-1451 Positron emission tomography in non-demented patients with Down Syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2017
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Down syndrome
- Focus Diagnostic use
- 29 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017